Table 3.
Clinical Outcomes between the Snare and Conventional Groups.
| Snare Group |
Conventional Group |
Unadjusted HR (95% CI) |
Multivariable HR * (95% CI) |
p Value | |
|---|---|---|---|---|---|
| Patient number (N = 262) | N = 20 | N = 242 | |||
| Primary outcome † | 25.9% (4) | 30.9% (53) | 0.887 (0.320–2.454) | 0.831 (0.296–2.334) | 0.817 |
| All-cause death | 12.0% (2) | 17.2% (24) | 0.684 (0.161–2.903) | 0.645 (0.148–2.809) | 0.604 |
| Cardiac death | 12.0% (2) | 12.1% (16) | 0.456 (0.104–1.992) | 0.453 (0.100–2.057) | 0.284 |
| Heart failure readmission | 15.6% (2) | 19.3% (34) | 1.181 (0.283–4.923) | 1.107 (0.261–4.686) | 0.819 |
| LVAD implantation | 0% (0) | 4.6% (6) | NA | NA | NA |
| Heart transplantation | 0% (0) | 7.0% (9) | NA | NA | NA |
| LV lead dislodgement or malfunction | 0% (0) | 5.8% (9) | NA | NA | NA |
The cumulative incidence of clinical outcomes is presented as Kaplan–Meier estimates during median follow-up of 22.6 ± 19.9 months. Number of events presented in parentheses. All p values were log-rank or Breslow p value in survival analysis. * Included covariables were age, baseline LVEF, and baseline LVESV. † The primary outcome was a composite of all-cause death or heart failure readmission. Abbreviations: LVAD, left ventricle assist device; LV, left ventricle; LVEF, left ventricle ejection fraction; LVESV, left ventricle end-systolic volume.